Please use this identifier to cite or link to this item:
Title: Association between caffeine intake and risk of Parkinson's disease among fast and slow metabolizers
Authors: Tan, E.-K.
Chua, E.
Fook-Chong, S.M.
Teo, Y.-Y. 
Yuen, Y.
Tan, L.
Zhao, Y.
Keywords: Caffeine
Parkinson's disease
Issue Date: Nov-2007
Citation: Tan, E.-K., Chua, E., Fook-Chong, S.M., Teo, Y.-Y., Yuen, Y., Tan, L., Zhao, Y. (2007-11). Association between caffeine intake and risk of Parkinson's disease among fast and slow metabolizers. Pharmacogenetics and Genomics 17 (11) : 1001-1005. ScholarBank@NUS Repository.
Abstract: INTRODUCTION: Cytochrome P450 1A2 (CYP 1A2) is responsible for more than 90% of caffeine clearance. A polymorphic variant of CYP1A2 (-163C>A) (rs762551) is associated with high CYP1A2 inducibility. Both caffeine and its main metabolite, paraxanthine, may be neuroprotective. The association between caffeine intake and risk of Parkinson's disease (PD) in fast and slow caffeine metabolizers has not been compared. OBJECTIVE: In a case-control study, we analyzed the relationship between caffeine intake and risk of PD in both fast and slow caffeine metabolizers. METHODS: All the study participants were recruited prospectively, and interviewed for information on the amount and duration of caffeine intake. Genotyping of the CYP1A2 variant was carried out using the allelic discrimination method. RESULTS: Out of 1000 participants who were initially screened, 886 consisting of 418 PD and 468 race, sex and age matched controls were included. No evidence existed to suggest any association between CYP1A2 and the onset of PD (P=0.08). A significant association was seen between caffeine intake and the onset of PD (P=2.01×10), with the odds ratio for moderate and high drinkers at 0.71 [95% confidence interval (CI): 0.50-1.00] and 0.47 (95% CI: 0.34-0.65), respectively against the low drinkers. Multivariate analysis revealed no evidence of any interaction effects of caffeine with CYP1A2 (P=0.956). CONCLUSION: The association between caffeine intake and risk of PD was similarly observed in both fast and slow caffeine metabolizers, supporting experimental evidence in animal models that both caffeine and its major metabolite, paraxanthine, are neuroprotective. © 2007 Lippincott Williams & Wilkins, Inc.
Source Title: Pharmacogenetics and Genomics
ISSN: 17446872
DOI: 10.1097/FPC.0b013e3282f09265
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on Sep 24, 2022


checked on Sep 16, 2022

Page view(s)

checked on Sep 22, 2022

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.